Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 674 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Edema Clear all
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2007 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972
View directory record Official record
Conditions
Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dorzolamide-timolol
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

NCT06850922
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RO7446603, Aflibercept, Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
70
States / cities
Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 8:05 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

NCT06942520
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
Genetic · Biological
Lead sponsor
Sierra Eye Associates
Other
Eligibility
25 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 30, 2026, 8:05 PM EDT
Active, not recruiting Not applicable Interventional

Research on Infarction With Open Arteries Using OCT and CMR

NCT02270359
View directory record Official record
Conditions
Myocardial Infarction
Interventions
OCT, CMR, contrast agent, Gadolinium
Device · Procedure · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 8:05 PM EDT
Withdrawn Phase 2 Interventional

Ranibizumab as a Rescue Therapy for Diabetic Macular Edema

NCT01253694
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
injection of 0.5 mg of Intravitreal Ranibizumab
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Norwich, Connecticut
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 30, 2026, 8:05 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

NCT04362241
View directory record Official record
Conditions
Retinopathy, Diabetic
Interventions
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Drug
Lead sponsor
Ophthalmic Consultants of the Capital Region
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 2 Interventional Results available

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

NCT03466099
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KVD001 Injection, Sham Procedure
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 30, 2026, 8:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Evaluate the SENSE Device's Ability to Detect TBI

NCT06828107
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
SENSE device
Device
Lead sponsor
Sense Diagnostics, LLC
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Gainesville, Florida • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 30, 2026, 8:05 PM EDT
Not yet recruiting Phase 2 Interventional

Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds

NCT07318792
View directory record Official record
Conditions
Wound Chronic Draining, Wound Closure
Interventions
Platelet-rich fibrin (PRF)
Device
Lead sponsor
Estar Medical dba Medical Technologies, LTD
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Bradenton, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 3 Interventional

Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)

NCT02624765
View directory record Official record
Conditions
Fetal Atrial Flutter Without Hydrops, Fetal Supraventricular Tachycardia Without Hydrops, Fetal Supraventricular Tachycardia With Hydrops
Interventions
Digoxin (monotherapy), Sotalol (monotherapy), Flecainide (monotherapy), Digoxin (dual therapy), Sotalol (dual therapy), Flecainide (dual therapy)
Drug
Lead sponsor
Edgar Jaeggi
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 1 Interventional

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

NCT00101764
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 8:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

NCT04108156
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
89
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 8:05 PM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

NCT02294656
View directory record Official record
Conditions
CYSTOID MACULAR EDEMA
Interventions
Ranibizumab,, Triamcinolone acetonide
Drug
Lead sponsor
Soll Eye
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients

NCT01948388
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
corticotrophin 80 units
Drug
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 30, 2026, 8:05 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Identifying Patients With Unrecognized Treatable Diabetic Macular Edema

NCT01934920
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 4 Interventional Results available

Use of Pulsed Electromagnetic Fields (PEMF) After Breast Reconstruction Surgery

NCT01262599
View directory record Official record
Conditions
Other Reconstructive Surgery
Interventions
Sham PEMF Device, Ivivi Torino II PEMF Device
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Early Phase 1 Interventional

Systemic Normothermia in Intracerebral Hemorrhage (ICH)

NCT02078037
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Arctic Sun cooling device, Standard of Care
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 30, 2026, 8:05 PM EDT
Withdrawn Phase 4 Interventional

Non-Responsive Diabetic Macular Edema and Spironolactone

NCT04853355
View directory record Official record
Conditions
Diabetic Maculopathy
Interventions
Spironolactone 50 mg
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 1 Interventional

A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

NCT02193113
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KVD001 Injection
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 30, 2026, 8:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325
View directory record Official record
Conditions
Thyroid Eye Disease (TED)
Interventions
VRDN-003, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Tuscon, Arizona • Inglewood, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 8:05 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 8:05 PM EDT
Recruiting Phase 3 Interventional

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

NCT07210515
View directory record Official record
Conditions
Complex Regional Pain Syndrome Type I
Interventions
Neridronate, Placebo
Drug
Lead sponsor
Ambros Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 8:05 PM EDT